Nasdaq:US$10.71 (+0.26) | HKEX:HK$17.46 (+0.58) | AIM:£1.80 (+0.02)
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2014-06-03

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer